
Opinion|Videos|May 14, 2024
Applying NCCN Guidelines in the Treatment of mBC
Britny Brown, PharmD, BCOP, discusses the importance of the NCCN guidelines in the treatment of metastatic breast cancer (mBC) and explains how the NCCN recommendations for CDK4/6 inhibitors differ for first-line patients.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Unproven Hantavirus Treatments Flood Social Media
2
Ketamine’s Expanding Role in Chronic Pain and Opioid-Sparing Therapy
3
FDA Expands Respiratory Options With First Single-Inhaler Triple Therapy for Asthma Maintenance
4
Navigating GLP-1 Access: A Pharmacy Technician’s Role
5



































































































































